Citations (17)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (1)
Kok-Lun Pang, Nie Yen Low & Kok-Yong Chin. (2020) A Review on the Role of Denosumab in Fracture Prevention. Drug Design, Development and Therapy 14, pages 4029-4051.
Read now
Read now
Articles from other publishers (16)
Mawson Wang & Markus J Seibel. (2023) Approach to the Patient With Bone Fracture: Making the First Fracture the Last. The Journal of Clinical Endocrinology & Metabolism 108:12, pages 3345-3352.
Crossref
Crossref
Mina Nicole Händel, Isabel Cardoso, Cecilie von Bülow, Jeanett Friis Rohde, Anja Ussing, Sabrina Mai Nielsen, Robin Christensen, Jean-Jacques Body, Maria Luisa Brandi, Adolfo Diez-Perez, Peyman Hadji, Muhammad Kassim Javaid, Willem Frederik Lems, Xavier Nogues, Christian Roux, Salvatore Minisola, Andreas Kurth, Thierry Thomas, Daniel Prieto-Alhambra, Serge Livio Ferrari, Bente Langdahl & Bo Abrahamsen. (2023) Fracture risk reduction and safety by osteoporosis treatment compared with placebo or active comparator in postmenopausal women: systematic review, network meta-analysis, and meta-regression analysis of randomised clinical trials. BMJ, pages e068033.
Crossref
Crossref
Giovanni Corrao, Annalisa Biffi, Gloria Porcu, Raffaella Ronco, Giovanni Adami, Rosaria Alvaro, Riccardo Bogini, Achille Patrizio Caputi, Luisella Cianferotti, Bruno Frediani, Davide Gatti, Stefano Gonnelli, Giovanni Iolascon, Andrea Lenzi, Salvatore Leone, Raffaella Michieli, Silvia Migliaccio, Tiziana Nicoletti, Marco Paoletta, Annalisa Pennini, Eleonora Piccirilli, Maurizio Rossini, Umberto Tarantino & Maria Luisa Brandi. (2023) Executive summary: Italian guidelines for diagnosis, risk stratification, and care continuity of fragility fractures 2021. Frontiers in Endocrinology 14.
Crossref
Crossref
Chelsea Ayers, Devan KansagaraBrittany LazurRongwei FuAmy Kwon & Curtis Harrod. (2023) Effectiveness and Safety of Treatments to Prevent Fractures in People With Low Bone Mass or Primary Osteoporosis: A Living Systematic Review and Network Meta-analysis for the American College of Physicians. Annals of Internal Medicine 176:2, pages 182-195.
Crossref
Crossref
Osnat Tell-Lebanon, Eyal Yaacobi, Nissim Ohana & Pnina Rotman-Pikielny. (2022) Osteoporosis Treatment After Osteoporotic Fractures: Data From a Single Medical Center. Endocrine Practice 28:12, pages 1221-1225.
Crossref
Crossref
K. Yu. Belova, E. V. Bublik, E. N. Gladkova, H. G. Gordjeladze, E. N. Dudinskaya, D. O. Ladygina, M. S. Morozova, Yu. V. Polyakova, L. E. Sivordova, V. G. Tanaev & O. M. Lesnyak. (2021) First results of the register of patients with osteoporosis included in the secondary fracture prevention services. Russian Journal of Geriatric Medicine:2, pages 211-218.
Crossref
Crossref
Ramona Dobre, Dan Alexandru Niculescu, Răzvan-Cosmin Petca, Răzvan-Ionuț Popescu, Aida Petca & Cătălina Poiană. (2021) Adherence to Anti-Osteoporotic Treatment and Clinical Implications after Hip Fracture: A Systematic Review. Journal of Personalized Medicine 11:5, pages 341.
Crossref
Crossref
M. K. Skjødt, S. Khalid, M. Ernst, K. H. Rubin, D. Martinez-Laguna, A. Delmestri, M. K. Javaid, C. Cooper, C. Libanati, E. Toth, B. Abrahamsen & D. Prieto-Alhambra. (2020) Secular trends in the initiation of therapy in secondary fracture prevention in Europe: a multi-national cohort study including data from Denmark, Catalonia, and the United Kingdom. Osteoporosis International 31:8, pages 1535-1544.
Crossref
Crossref
Ning Zhang, Zong-Kang Zhang, Yuanyuan Yu, Zhenjian Zhuo, Ge Zhang & Bao-Ting Zhang. (2020) Pros and Cons of Denosumab Treatment for Osteoporosis and Implication for RANKL Aptamer Therapy. Frontiers in Cell and Developmental Biology 8.
Crossref
Crossref
Pilar Sáez-López, Iñigo Etxebarria-Foronda, Maria Pilar Mesa Lampre, Noelia Alonso García & Natalia Sánchez Hernández. (2019) Efficacy, cost, and aspects to take into account in the treatment of osteoporosis in the elderly. Revista Española de Geriatría y Gerontología 54:3, pages 156-167.
Crossref
Crossref
Paul J. Mitchell & Markus J. Seibel. 2019. Secondary Fracture Prevention. Secondary Fracture Prevention
1
7
.
Amanda D. Schnell, Jeffrey R. Curtis & Kenneth G. Saag. (2018) Importance of Recent Fracture as Predictor of Imminent Fracture Risk. Current Osteoporosis Reports 16:6, pages 738-745.
Crossref
Crossref
Olga Růžičková, Zdenko Killinger, Petr Kasalický, Lisa Hamilton, Roman Tyl, Soňa Tomková & Lama Kalouche-Khalil. (2018) Real-world Management of Women with Postmenopausal Osteoporosis Treated with Denosumab: A Prospective Observational Study in the Czech Republic and Slovakia. Advances in Therapy 35:10, pages 1713-1728.
Crossref
Crossref
Emma D. Deeks. (2018) Denosumab: A Review in Postmenopausal Osteoporosis. Drugs & Aging 35:2, pages 163-173.
Crossref
Crossref
T. Saito, J. M. Sterbenz, S. Malay, L. Zhong, M. P. MacEachern & K. C. Chung. (2017) Effectiveness of anti-osteoporotic drugs to prevent secondary fragility fractures: systematic review and meta-analysis. Osteoporosis International 28:12, pages 3289-3300.
Crossref
Crossref
N. C. W. Harvey, E. V. McCloskey, P. J. Mitchell, B. Dawson-Hughes, D. D. Pierroz, J.-Y. Reginster, R. Rizzoli, C. Cooper & J. A. Kanis. (2017) Mind the (treatment) gap: a global perspective on current and future strategies for prevention of fragility fractures. Osteoporosis International 28:5, pages 1507-1529.
Crossref
Crossref